[Platelet activation in lung cancer]

Area of Science:

• Hematology
• Oncology
• Thrombosis Research

Background:

• Primary hemostasis involves platelet aggregation forming a thrombus, with adenosine diphosphate (ADP) and thrombin as key agonists.
• Previous research indicated hypercoagulability and hyperfibrinogenemia in lung cancer patients, predicting thromboembolic disease.
• Platelet count and aggregation are crucial components of primary hemostasis.

Purpose of the Study:

• To investigate whether lung cancer patients exhibit hyperaggregability, correlating with previously observed hypercoagulability.
• To evaluate abnormalities in primary hemostasis, specifically platelet count and aggregation, in lung cancer patients.
• To determine the relationship between platelet aggregation, hyperfibrinogenemia, and thromboembolic disease in lung cancer.

Main Methods:

• Study included 101 lung cancer patients (pre-therapy) and 72 blood donors.
• Platelet aggregation was assessed using agonists like collagen and adenosine diphosphate (ADP) at low concentrations.
• Platelet count and aggregation were evaluated to identify primary hemostasis abnormalities.

Main Results:

• Lung cancer patients demonstrated significant hyperaggregability when platelets were stimulated by ADP (p ≤ 0.01).
• Hyperaggregability was influenced by histological type, age, and platelet count, but not by cancer development stage.
• Platelet activation in response to ADP was observed, independent of hyperfibrinogenemia and thromboembolic disease occurrence.

Conclusions:

• Patients with lung cancer exhibit platelet hyperaggregability, evidenced by enhanced response to ADP stimulation.
• This platelet activation is associated with specific cancer histology and is independent of hyperfibrinogenemia.
• The findings suggest a distinct platelet response in lung cancer, separate from hypercoagulability-related factors.